Affordable Access

Publisher Website

Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.

Authors
Type
Published Article
Journal
Expert Opinion on Investigational Drugs
1744-7658
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
19
Issue
12
Pages
1591–1602
Identifiers
DOI: 10.1517/13543784.2010.535515
PMID: 21073357
Source
Medline

Abstract

Although early, results of the first trials of afamelanotide for PP are promising and the risk-safety profile appears favorable today. We expect afamelanotide and analogs thereof to be a prospective therapeutic tool in light-related skin diseases, and in future this drug class might prove effectiveness in other medical conditions.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments